China
· Delayed Price · Currency is CNY DaShenLin Pharmaceutical Group Statistics
Total Valuation
DaShenLin Pharmaceutical Group has a market cap or net worth of CNY 15.28 billion. The enterprise value is 18.65 billion.
| Market Cap | 15.28B |
| Enterprise Value | 18.65B |
Important Dates
The next estimated earnings date is Tuesday, October 29, 2024.
| Earnings Date | Oct 29, 2024 |
| Ex-Dividend Date | Jun 21, 2024 |
Share Statistics
DaShenLin Pharmaceutical Group has 1.14 billion shares outstanding. The number of shares has decreased by -0.00% in one year.
| Shares Outstanding | 1.14B |
| Shares Change (YoY) | -0.00% |
| Shares Change (QoQ) | -0.82% |
| Owned by Insiders (%) | 64.58% |
| Owned by Institutions (%) | 12.70% |
| Float | 403.43M |
Valuation Ratios
The trailing PE ratio is 16.77 and the forward PE ratio is 11.95.
| PE Ratio | 16.77 |
| Forward PE | 11.95 |
| PS Ratio | 0.59 |
| PB Ratio | 2.15 |
| P/FCF Ratio | 9.35 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.21, with an EV/FCF ratio of 11.41.
| EV / Earnings | 20.57 |
| EV / Sales | 0.72 |
| EV / EBITDA | 6.21 |
| EV / EBIT | 12.61 |
| EV / FCF | 11.41 |
Financial Position
The company has a current ratio of 0.93, with a Debt / Equity ratio of 85.63.
| Current Ratio | 0.93 |
| Quick Ratio | 0.55 |
| Debt / Equity | 85.63 |
| Debt / EBITDA | 2.39 |
| Debt / FCF | 4.39 |
| Interest Coverage | 6.09 |
Financial Efficiency
Return on equity (ROE) is 12.22% and return on invested capital (ROIC) is 6.40%.
| Return on Equity (ROE) | 12.22% |
| Return on Assets (ROA) | 3.99% |
| Return on Capital (ROIC) | 6.40% |
| Revenue Per Employee | 569,323 |
| Profits Per Employee | 19,942 |
| Employee Count | 45,466 |
| Asset Turnover | 1.12 |
| Inventory Turnover | 4.03 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.78% in the last 52 weeks. The beta is 0.23, so DaShenLin Pharmaceutical Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | -47.78% |
| 50-Day Moving Average | 13.16 |
| 200-Day Moving Average | 20.26 |
| Relative Strength Index (RSI) | 52.34 |
| Average Volume (20 Days) | 10,654,100 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DaShenLin Pharmaceutical Group had revenue of CNY 25.88 billion and earned 906.67 million in profits. Earnings per share was 0.80.
| Revenue | 25.88B |
| Gross Profit | 8.91B |
| Operating Income | 1.48B |
| Pretax Income | 1.30B |
| Net Income | 906.67M |
| EBITDA | 1.72B |
| EBIT | 1.48B |
| Earnings Per Share (EPS) | 0.80 |
Balance Sheet
The company has 5.06 billion in cash and 7.17 billion in debt, giving a net cash position of -2.11 billion or -1.85 per share.
| Cash & Cash Equivalents | 5.06B |
| Total Debt | 7.17B |
| Net Cash | -2.11B |
| Net Cash Per Share | -1.85 |
| Equity (Book Value) | 8.37B |
| Book Value Per Share | 6.24 |
| Working Capital | -813.55M |
Cash Flow
In the last 12 months, operating cash flow was 3.46 billion and capital expenditures -1.83 billion, giving a free cash flow of 1.63 billion.
| Operating Cash Flow | 3.46B |
| Capital Expenditures | -1.83B |
| Free Cash Flow | 1.63B |
| FCF Per Share | 1.44 |
Margins
Gross margin is 34.42%, with operating and profit margins of 5.72% and 3.50%.
| Gross Margin | 34.42% |
| Operating Margin | 5.72% |
| Pretax Margin | 5.03% |
| Profit Margin | 3.50% |
| EBITDA Margin | 6.63% |
| EBIT Margin | 5.72% |
| FCF Margin | 6.31% |
Dividends & Yields
This stock pays an annual dividend of 0.62, which amounts to a dividend yield of 4.62%.
| Dividend Per Share | 0.62 |
| Dividend Yield | 4.62% |
| Dividend Growth (YoY) | -48.33% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 41.19% |
| Buyback Yield | 0.00% |
| Shareholder Yield | 4.62% |
| Earnings Yield | 5.96% |
| FCF Yield | 10.69% |
Stock Splits
The last stock split was on June 9, 2023. It was a forward split with a ratio of 1.2.
| Last Split Date | Jun 9, 2023 |
| Split Type | Forward |
| Split Ratio | 1.2 |